Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its...

|About: Abbott Laboratories (ABT)|By:, SA News Editor

Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response.